Biotech companies entering new markets must consider talent availability, reimbursement strategy, and regional expertise early in development, according to Kirsten Detrick, chief representative, USA, at the Basel Area Life Sciences Supercluster.
Kirsten Detrick
Advertisement
Kirsten Detrick is chief representative, USA, at Basel Area Life Sciences Supercluster.
Articles by Kirsten Detrick
Advertisement
Latest Updated Articles
Advertisement
Advertisement